Search

everythinglearnresearchcommunity

for

Search:↓

Early balding, especially frontal, increases prostate cancer risk; more research needed.

PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

Higher cholesterol levels increase aggressive prostate cancer risk.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Early balding at 40 increases prostate cancer risk.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.

Health warnings and public health actions led to a significant drop in flutamide prescriptions for women, but off-label use still continues.

PSA could be a marker for hyperandrogenism in women, but more research is needed.

Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Higher DHT in male baldness may protect against prostate cancer.

The healthcare for transgender veterans could be better with a more unified team approach.